Strategic Partnerships Potential buyers or partners include radiopharmaceutical developers and contract manufacturing organizations (CMOs) seeking alpha-particle therapies and theranostic platforms. Opportunities exist with Isoray and PharmaLogic-type collaborators to co-develop and manufacture VMT-01 and VMT-α-NET assets, accelerating clinical progression and scale.

Academic Collaboration Phase 1 imaging and subsequent therapy trials at leading academic institutions present a pathway for research collaborations, joint grant opportunities, and sponsored studies to validate targeting peptides and imaging diagnostics, creating upside through co-funded trials and data generation.

Clinical Pipeline Targeted outreach to cancer centers treating melanoma and neuroendocrine tumors could drive investigator-initiated trials, early access discussions, and potential future procurement agreements for theranostic compounds once early-phase efficacy signals emerge.

Manufacturing & CDMO Engage with radiopharma CMOs for scalable production of VMT-01 and VMT-α-NET radiopharmaceuticals and associated diagnostics, highlighting the need for specialized labeling, quality control, and regulatory alignment to support GMP-compliant manufacturing.

Funding & Growth With existing funding and a recent merger history, there is an opening to approach investors and grant bodies about upcoming milestones, milestones, and potential exit scenarios, while framing partnerships that de-risk capital-intensive alpha therapies.